JP2020529996A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020529996A5 JP2020529996A5 JP2020505487A JP2020505487A JP2020529996A5 JP 2020529996 A5 JP2020529996 A5 JP 2020529996A5 JP 2020505487 A JP2020505487 A JP 2020505487A JP 2020505487 A JP2020505487 A JP 2020505487A JP 2020529996 A5 JP2020529996 A5 JP 2020529996A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- individual
- daily dose
- plasma concentration
- agent according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023014110A JP2023065372A (ja) | 2017-08-04 | 2023-02-01 | 肥大型心筋症の治療で使用するためのマバカムテン |
| JP2024192836A JP2025020292A (ja) | 2017-08-04 | 2024-11-01 | 肥大型心筋症の治療で使用するためのマバカムテン |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762541591P | 2017-08-04 | 2017-08-04 | |
| US62/541,591 | 2017-08-04 | ||
| US201762584537P | 2017-11-10 | 2017-11-10 | |
| US62/584,537 | 2017-11-10 | ||
| US201862639922P | 2018-03-07 | 2018-03-07 | |
| US62/639,922 | 2018-03-07 | ||
| US201862671585P | 2018-05-15 | 2018-05-15 | |
| US62/671,585 | 2018-05-15 | ||
| PCT/US2018/045180 WO2019028360A1 (en) | 2017-08-04 | 2018-08-03 | MAVACAMTEN FOR USE IN THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023014110A Division JP2023065372A (ja) | 2017-08-04 | 2023-02-01 | 肥大型心筋症の治療で使用するためのマバカムテン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020529996A JP2020529996A (ja) | 2020-10-15 |
| JP2020529996A5 true JP2020529996A5 (https=) | 2021-10-07 |
Family
ID=63350605
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505487A Pending JP2020529996A (ja) | 2017-08-04 | 2018-08-03 | 肥大型心筋症の治療で使用するためのマバカムテン |
| JP2023014110A Pending JP2023065372A (ja) | 2017-08-04 | 2023-02-01 | 肥大型心筋症の治療で使用するためのマバカムテン |
| JP2024192836A Pending JP2025020292A (ja) | 2017-08-04 | 2024-11-01 | 肥大型心筋症の治療で使用するためのマバカムテン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023014110A Pending JP2023065372A (ja) | 2017-08-04 | 2023-02-01 | 肥大型心筋症の治療で使用するためのマバカムテン |
| JP2024192836A Pending JP2025020292A (ja) | 2017-08-04 | 2024-11-01 | 肥大型心筋症の治療で使用するためのマバカムテン |
Country Status (28)
| Country | Link |
|---|---|
| US (6) | US20200054636A1 (https=) |
| EP (2) | EP3661514B1 (https=) |
| JP (3) | JP2020529996A (https=) |
| KR (2) | KR20200035973A (https=) |
| CN (2) | CN111182901A (https=) |
| AU (2) | AU2018311974B2 (https=) |
| CA (1) | CA3071948A1 (https=) |
| DK (1) | DK3661514T3 (https=) |
| ES (1) | ES3055679T3 (https=) |
| FI (1) | FI3661514T3 (https=) |
| HR (1) | HRP20251598T1 (https=) |
| HU (1) | HUE073047T2 (https=) |
| IL (2) | IL322175A (https=) |
| LT (1) | LT3661514T (https=) |
| MA (1) | MA49760B1 (https=) |
| MX (3) | MX2020001406A (https=) |
| MY (1) | MY208231A (https=) |
| PL (1) | PL3661514T3 (https=) |
| PT (1) | PT3661514T (https=) |
| RS (1) | RS67534B1 (https=) |
| RU (1) | RU2020109345A (https=) |
| SG (2) | SG10202112960QA (https=) |
| SI (1) | SI3661514T1 (https=) |
| SM (1) | SMT202500413T1 (https=) |
| TW (1) | TWI907332B (https=) |
| UA (1) | UA130213C2 (https=) |
| UY (1) | UY37834A (https=) |
| WO (1) | WO2019028360A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019144041A1 (en) | 2018-01-19 | 2019-07-25 | Cytokinetics, Inc. | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| JP7610985B2 (ja) | 2018-06-26 | 2025-01-09 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| WO2020257609A1 (en) * | 2019-06-21 | 2020-12-24 | MyoKardia, Inc. | Diagnostics and treatments for cardiac disease |
| CN110698415B (zh) * | 2019-10-21 | 2023-05-09 | 上海先行医药开发有限公司 | 一种肌球蛋白抑制剂及其制备方法和用途 |
| EP4054588A4 (en) * | 2019-11-10 | 2023-12-13 | MyoKardia, Inc. | Methods of treatment with myosin modulator |
| HUE069154T2 (hu) * | 2020-01-28 | 2025-02-28 | Assia Chem Ind Ltd | A mavakamten szilárd állapotú formái és eljárás elõállításukra |
| MX2023002024A (es) * | 2020-08-28 | 2023-05-10 | Myokardia Inc | Métodos de tratamiento con modulador de miosina. |
| WO2022105852A1 (zh) | 2020-11-20 | 2022-05-27 | 江苏恒瑞医药股份有限公司 | 三嗪二酮类衍生物、其制备方法及其在医药上的应用 |
| US20240082248A1 (en) * | 2021-02-01 | 2024-03-14 | Dr. Reddy's Laboratories Limited | Process for preparation of mavacamten and solid state forms thereof |
| CN117083275A (zh) | 2021-03-04 | 2023-11-17 | 赛特凯恩蒂克公司 | 心脏肌节抑制剂 |
| CN112939876A (zh) * | 2021-03-10 | 2021-06-11 | 杭州科巢生物科技有限公司 | Mavacamten的晶型I及其制备方法 |
| WO2022189599A1 (en) | 2021-03-12 | 2022-09-15 | Sandoz Ag | Crystalline forms of mavacamten for the treatment of hcm |
| PT4370116T (pt) * | 2021-07-16 | 2025-03-14 | Cytokinetics Inc | Regimes de administração de aficamten para o tratamento da cardiomiopatia hipertrófica obstrutiva |
| US20240389972A1 (en) * | 2021-09-24 | 2024-11-28 | Koninklijke Philips N.V. | METHODS AND SYSTEMS FOR GENERATING LIKELIHOOD OF HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF) |
| JP2025534288A (ja) | 2022-09-26 | 2025-10-15 | エッジワイズ セラピューティクス， インコーポレイテッド | １，４－ジヒドロキナゾリノン化合物およびその使用 |
| WO2024097284A1 (en) * | 2022-11-02 | 2024-05-10 | MyoKardia, Inc. | Mavacamten and derivatives thereof for use in treating atrial dysfunction |
| EP4688756A1 (en) | 2023-03-27 | 2026-02-11 | Edgewise Therapeutics, Inc. | Quinazoline dione compounds and uses thereof |
| WO2024206339A1 (en) | 2023-03-27 | 2024-10-03 | Edgewise Therapeutics, Inc. | Quinolinone amide compounds and uses thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202000071T1 (it) * | 2013-06-21 | 2020-03-13 | Myokardia Inc | Composti di pirimidinadione contro le condizioni cardiache |
-
2018
- 2018-08-03 CA CA3071948A patent/CA3071948A1/en active Pending
- 2018-08-03 RU RU2020109345A patent/RU2020109345A/ru unknown
- 2018-08-03 KR KR1020207004507A patent/KR20200035973A/ko not_active Ceased
- 2018-08-03 EP EP18759209.2A patent/EP3661514B1/en active Active
- 2018-08-03 PL PL18759209.2T patent/PL3661514T3/pl unknown
- 2018-08-03 MA MA49760A patent/MA49760B1/fr unknown
- 2018-08-03 HR HRP20251598TT patent/HRP20251598T1/hr unknown
- 2018-08-03 RS RS20251281A patent/RS67534B1/sr unknown
- 2018-08-03 LT LTEPPCT/US2018/045180T patent/LT3661514T/lt unknown
- 2018-08-03 UA UAA202001501A patent/UA130213C2/uk unknown
- 2018-08-03 SG SG10202112960QA patent/SG10202112960QA/en unknown
- 2018-08-03 PT PT187592092T patent/PT3661514T/pt unknown
- 2018-08-03 ES ES18759209T patent/ES3055679T3/es active Active
- 2018-08-03 MX MX2020001406A patent/MX2020001406A/es unknown
- 2018-08-03 FI FIEP18759209.2T patent/FI3661514T3/fi active
- 2018-08-03 HU HUE18759209A patent/HUE073047T2/hu unknown
- 2018-08-03 SG SG11202000549TA patent/SG11202000549TA/en unknown
- 2018-08-03 AU AU2018311974A patent/AU2018311974B2/en active Active
- 2018-08-03 IL IL322175A patent/IL322175A/en unknown
- 2018-08-03 SM SM20250413T patent/SMT202500413T1/it unknown
- 2018-08-03 TW TW107127110A patent/TWI907332B/zh active
- 2018-08-03 EP EP25196218.9A patent/EP4659806A3/en active Pending
- 2018-08-03 KR KR1020257024814A patent/KR20250116181A/ko active Pending
- 2018-08-03 MY MYPI2020000493A patent/MY208231A/en unknown
- 2018-08-03 WO PCT/US2018/045180 patent/WO2019028360A1/en not_active Ceased
- 2018-08-03 JP JP2020505487A patent/JP2020529996A/ja active Pending
- 2018-08-03 SI SI201831270T patent/SI3661514T1/sl unknown
- 2018-08-03 CN CN201880050881.4A patent/CN111182901A/zh active Pending
- 2018-08-03 CN CN202410743651.3A patent/CN118593507A/zh active Pending
- 2018-08-03 IL IL272300A patent/IL272300B2/en unknown
- 2018-08-03 DK DK18759209.2T patent/DK3661514T3/da active
- 2018-08-06 UY UY0001037834A patent/UY37834A/es not_active Application Discontinuation
-
2019
- 2019-03-26 US US16/364,322 patent/US20200054636A1/en not_active Abandoned
-
2020
- 2020-02-04 MX MX2024008096A patent/MX2024008096A/es unknown
- 2020-02-04 MX MX2024000348A patent/MX2024000348A/es unknown
-
2022
- 2022-03-23 US US17/701,863 patent/US20220226324A1/en not_active Abandoned
- 2022-06-16 US US17/842,389 patent/US20220313695A1/en not_active Abandoned
-
2023
- 2023-02-01 JP JP2023014110A patent/JP2023065372A/ja active Pending
-
2024
- 2024-06-07 AU AU2024203872A patent/AU2024203872A1/en active Pending
- 2024-09-06 US US18/827,049 patent/US20240423981A1/en not_active Abandoned
- 2024-11-01 JP JP2024192836A patent/JP2025020292A/ja active Pending
-
2025
- 2025-03-18 US US19/082,967 patent/US20250213565A1/en active Pending
- 2025-08-01 US US19/288,391 patent/US20260007671A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020529996A5 (https=) | ||
| JP4938905B2 (ja) | 選択的ｓ１ｐ１レセプターアゴニストの投与法 | |
| JP6309454B2 (ja) | 癌の併用処置 | |
| US8697662B2 (en) | Methods for treating Kaposi sarcoma | |
| RU2020109345A (ru) | Применение мавакамтена для лечения гипертрофической кардиомиопатии | |
| JP6858716B2 (ja) | 心筋ミオシン活性化剤と洞房結節Ｉｆ電流阻害剤の併用療法 | |
| JP2015526458A5 (https=) | ||
| JP5643213B2 (ja) | 肥大性心筋症治療用のホスホジエステラーゼタイプＩＩＩ（ＰＤＥＩＩＩ）インヒビターまたはＣａ２＋感作剤 | |
| TW202423423A (zh) | 治療非阻塞性肥厚性心肌病之方法 | |
| US20240261242A1 (en) | Methods of intravenously administering sotalol | |
| US20240366596A1 (en) | Treatment of hfpef in post-menopausal women with an sgc stimulator | |
| CA2753754C (en) | Methods for treating schizophrenia | |
| JP6028983B2 (ja) | ビダラビンによる心房細動治療 | |
| JP7439297B2 (ja) | 肥大型心筋症治療用薬学組成物およびその組成物を用いた治療方法 | |
| TW202539641A (zh) | 用於治療心臟病之方法 | |
| WO2022125551A1 (en) | Method of treating hereditary hemorrhagic telangiectasia using pazopanib | |
| Efanov et al. | ARTERIAL HYPERTENSION CONTROL IN THE EXTREME NORTH POPULATION OF THE EMPLOYABLE AGE: PP. 34.397 | |
| Rekovets et al. | INFLUENCE DIFFERENT TYPE OF ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH ARTERIAL HYPERTENSION (AH) AND METABOLIC SYNDROME (MS) ON INSULIN RESISTANCE DEPENDS ON SEX: PP. 34.398 | |
| HK40103286A (zh) | 治疗与s1p₁受体相关的病症的方法 | |
| RU2022110225A (ru) | Применение мавакамтена для лечения гипертрофической кардиомиопатии | |
| Nikolaeva et al. | Results of the Cardiological Study Invest: A New Word in the Therapy of Patients with Hypertension | |
| M-Castillo et al. | EFFECT OF MANIDIPINE IN CHRONIC KIDNEY DISEASE PATIENTS WITH METABOLIC SYNDROME. PLASENCIA STUDY: PP. 34.399 | |
| Ferrara et al. | HIGH TG/HDL RATIO HELPS IN THE EVALUATION OF CV RISK OF HYPERTENSIVE PATIENTS WITHOUT METABOLIC SYNDROME: PP. 34.400 | |
| JP2005519072A (ja) | 心不全、他の加齢関連臓器機能不全および加齢関連障害の予防のための、ならびに寿命を延長するための、ナトリウム−水素交換阻害剤であるカリポライドとａｃｅ阻害剤との組み合わせ製剤 | |
| HK1152878B (en) | Dosing regimen for a selective sip1 receptor agonist |